Artelo biosciences provides business update and reports fiscal 2024 year-end financial results

Solana beach, calif., march 03, 2025 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended december 31, 2024.
ARTL Ratings Summary
ARTL Quant Ranking